《生命科学》 2016, 28(4): 475-479

PD-1/PD-L1抗体在肿瘤临床治疗中的应用

魏木兰，王艳林，秦　烨*

(三峡大学医学院肿瘤微环境与免疫治疗湖北省重点实验室，宜昌 443002)

摘　要：摘　要：PD-1 是主要表达在活化T 细胞上的免疫抑制性受体，与表达在肿瘤细胞表面的配体PD-L1 结合，通过降低T 细胞的免疫应答，使肿瘤免疫逃逸。靶向PD-1/PD-L1 这一信号通路的单克隆抗体类药物的研发是当前抗肿瘤治疗领域的研究热点。目前，已有多项临床研究提示，PD-1 及PD-L1 抗体药物治疗肿瘤的疗效显著且不良反应较小，有望改善部分晚期肿瘤患者的预后。

PD-1 and PD-L1 antibody in clinical cancer therapy

WEI Mu-Lan， WANG Yan-Lin， QIN Ye*

(Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy， Medical College， Three Gorges University， Yichang 443002， China)

Abstract: Abstract: Programmed cell death-1(PD-1) is an immuno-inhibitory receptor mainly expressed in actived T cells. When binding to its ligand PD-L1 which is expressed on the surface of tumor cells， PD-1 could transduce a signal that inhibits T cell-mediated immune response and contributes to tumor immune evasion. Recently， the development of monoclonal antibodies targeting the pathway of PD-1/PD-L1 is the focus of antitumor treatment. And many clinical trials have shown that PD-1/PD-L1 antibodies have profound effects on antitumor treatment with low toxicity， expecting to improve the prognosis of patients with advanced tumors.